“By acquiring Esperion, we can bring our research capabilities to bear on an emerging new area which has potentially significant beneficial impact on patients. Epidemiologic data and drug intervention trials both support a strong correlation between higher HDL levels and improvements in morbidity and mortality.”
Hank McKinnell, Pfizer Chairman and CEO
December 21, 2003
You will automatically
be redirected to the
Pfizer Corporate Web Site
in 20 seconds.
|